Literature DB >> 12777910

The risk factors and time course of sepsis and organ dysfunction after burn trauma.

John Fitzwater1, Gary F Purdue, John L Hunt, Grant E O'Keefe.   

Abstract

BACKGROUND: Sepsis and organ dysfunction are common and likely contribute to death after burn trauma. We sought to define relationships between sepsis, severe multiple organ dysfunction (MOD), and death after burn trauma.
METHODS: Adults with > or = 20% total body surface area burns were prospectively enrolled. Information regarding infection, severity of sepsis, and organ failure was collected daily. Risk factors (e.g., age, burn size, shock) were analyzed for their association with severe MOD, complicated sepsis, and death. We characterized the temporal relationship between organ failure and sepsis.
RESULTS: Of 175 patients, 27% developed severe MOD, 17% developed complicated sepsis, and 22% died. Full-thickness burn size, age, and inhalation injury were associated with MOD, sepsis, and death. Infection preceded MOD in 83% of patients with both. A base deficit of > or = 6 mEq/L at 24 hours after injury was associated with death.
CONCLUSION: When it occurs, severe MOD is usually preceded by infection. In addition, an elevated base deficit at 24 hours and septic shock are the most important factors associated with and possibly contributing to death after burn trauma.

Entities:  

Mesh:

Year:  2003        PMID: 12777910     DOI: 10.1097/01.TA.0000029382.26295.AB

Source DB:  PubMed          Journal:  J Trauma        ISSN: 0022-5282


  66 in total

1.  Aging and the pathogenic response to burn.

Authors:  Meenakshi Rani; Martin G Schwacha
Journal:  Aging Dis       Date:  2011-07-04       Impact factor: 6.745

Review 2.  Outcome of acute kidney injury in severe burns: a systematic review and meta-analysis.

Authors:  Nele Brusselaers; Stan Monstrey; Kirsten Colpaert; Johan Decruyenaere; Stijn I Blot; Eric A J Hoste
Journal:  Intensive Care Med       Date:  2010-03-24       Impact factor: 17.440

3.  Predicting mortality in burn patients with bacteraemia.

Authors:  Alexandra Ceniceros; Sonia Pértega; Rita Galeiras; Mónica Mourelo; Eugenia López; Javier Broullón; Dolores Sousa; David Freire
Journal:  Infection       Date:  2015-10-08       Impact factor: 3.553

Review 4.  Sex differences and estrogen modulation of the cellular immune response after injury.

Authors:  Melanie D Bird; John Karavitis; Elizabeth J Kovacs
Journal:  Cell Immunol       Date:  2008-02-21       Impact factor: 4.868

Review 5.  Antiseptics for burns.

Authors:  Gill Norman; Janice Christie; Zhenmi Liu; Maggie J Westby; Jayne M Jefferies; Thomas Hudson; Jacky Edwards; Devi Prasad Mohapatra; Ibrahim A Hassan; Jo C Dumville
Journal:  Cochrane Database Syst Rev       Date:  2017-07-12

Review 6.  Management and prevention of drug resistant infections in burn patients.

Authors:  Roohi Vinaik; Dalia Barayan; Shahriar Shahrokhi; Marc G Jeschke
Journal:  Expert Rev Anti Infect Ther       Date:  2019-08-04       Impact factor: 5.091

7.  Dendritic cell modification of neutrophil responses to infection after burn injury.

Authors:  Julia Bohannon; Weihua Cui; Edward Sherwood; Tracy Toliver-Kinsky
Journal:  J Immunol       Date:  2010-08-02       Impact factor: 5.422

8.  Impact of burn priming on immune and metabolic functions of whole Liver in a rat cecal ligation and puncture model.

Authors:  John Sa Mattick; Qian Yang; Mehmet A Orman; Marianthi G Ierapetritou; Francois Berthiaume; Stephen C Gale; Ioannis P Androulakis
Journal:  Int J Burns Trauma       Date:  2013-01-24

Review 9.  Prophylactic antibiotics for burns patients: systematic review and meta-analysis.

Authors:  Tomer Avni; Ariela Levcovich; Dean D Ad-El; Leonard Leibovici; Mical Paul
Journal:  BMJ       Date:  2010-02-15

10.  Flt3 Ligand Treatment Attenuates T Cell Dysfunction and Improves Survival in a Murine Model of Burn Wound Sepsis.

Authors:  Naeem K Patil; Julia K Bohannon; Liming Luan; Yin Guo; Benjamin Fensterheim; Antonio Hernandez; Jingbin Wang; Edward R Sherwood
Journal:  Shock       Date:  2017-01       Impact factor: 3.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.